Source comparison
BPC-157 for Men: Research Dosages & Administration Comparison
Subcutaneous (systemic) 250–500 mcg daily 14–21 days for measurable tissue repair Broad distribution. Reaches multiple injury sites simultaneously Best for diffuse soft-tissue inflammation or gut healing Intramuscular (localized) 200–400 mcg near injury site 7
This comparison does not assign a generated winner or score.
- Subcutaneous (systemic)
- 250–500 mcg daily
- 14–21 days for measurable tissue repair
- Broad distribution. Reaches multiple injury sites simultaneously
- Best for diffuse soft-tissue inflammation or gut healing
- Intramuscular (localized)
- 200–400 mcg near injury site
- 7–14 days for localized collagen deposition
- Direct delivery to injury. Higher concentration at target tissue
- Preferred for specific tendon or ligament tears
- Oral (experimental)
- 500–1000 mcg daily
- 21–28 days. Slower absorption through GI tract
- Non-invasive, potential mucosal contact for gut repair
- Limited bioavailability. Studies show 30–40% absorption vs injection
- Twice-daily split dose
- 250 mcg AM/PM
- Maintains plasma levels above therapeutic threshold
- Matches peptide's 4–6 hour half-life more effectively
- Recommended for chronic injuries requiring sustained signaling
- The localized injection approach. Placing the peptide within 1–2 cm of the injury site. Produces the fastest measurable effects because VEGFR2 density is highest at damaged tissue. Systemic subcutaneous administration works for diffuse injuries (multiple joint inflammation, widespread muscle soreness) but requires 2–3× longer to produce visible improvements.